|
US2015216988A1
|
|
Injectable flowable composition buprenorphine
|
|
GB201419430D0
|
|
Dopamine D3 receptor antagonist compounds
|
|
GB201419433D0
|
|
Dopamine D3 receptor antagonist compounds
|
|
AU2014201777A1
|
|
Improvements in and relating to medicinal compositions
|
|
AU2014201779A1
|
|
Improved medicinal compositions comprising buprenorphine and naloxone
|
|
AU2014201782A1
|
|
Improved medicinal compositions comprising buprenorphine and naltrexone
|
|
GB201404139D0
|
|
Sustained release buprenorphine solution formulations
|
|
US2013203796A1
|
|
Injectable flowable composition comprising buprenorphine
|
|
GB201009549D0
|
|
Injectable flowable composition comprising buprenorphine
|
|
GB201009546D0
|
|
Microparticle buprenorphine suspension
|
|
NZ616269A
|
|
Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and nalmefene
|
|
NZ616264A
|
|
Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and naltrexone
|
